On the stock market since 2021, it operates in the world of health and science. It has 525 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 23% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades 48% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 20% a year on average.
Sales run at $256.2M a year. A small number, but proof the product has real buyers.
A loss of $54.6M against $256.2M in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
Over the last 12 months, executives reported 64 sells against just 9 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, FNA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: FNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.